Dyadic secures Japan patent for protein expression technology
Dyadic International, Inc. announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone significantly enhances the company's global intellectual property portfolio and reinforces its C1 and Dapibus™ microbial production platforms. The patent is a key component of Dyadic's international growth strategy, particularly in Japan, where it is collaborating with Intralink to expand commercial opportunities. The company aims to capitalize on the growing demand for scalable recombinant protein solutions in strategic markets.
Key Highlights
- Japan Patent Office allowed claims for Dyadic's protein expression technology.
- Strengthens global intellectual property portfolio for C1 and Dapibus™ platforms.
- Part of international growth strategy targeting Japan's biotechnology market.
- Engaged Intralink for business development and market expansion in Japan.
- President & COO to meet with prospective partners in Japan in early July.
- Positions Dyadic to meet global demand for recombinant protein solutions.
Price Impact
More from DYAI
Dyadic International faces Nasdaq delisting over bid price, equity rules
Dyadic C1 Platform Sees Accelerated Interest for Ebola & Commercial Use
Dyadic C1 Platform Gains Traction for Ebola Preparedness & Commercial Use